{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:23:33Z","timestamp":1768641813270,"version":"3.49.0"},"reference-count":96,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"British Columbia Provincial Health Services Authority"},{"name":"Jack Bell Chair in Schizophrenia"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The second generation antipsychotic drugs represent the most common form of pharmacotherapy for schizophrenia disorders. It is now well established that most of the second generation drugs cause metabolic side-effects. Risperidone and its active metabolite paliperidone (9-hydroxyrisperidone) are two commonly used antipsychotic drugs with moderate metabolic liability. However, there is a dearth of preclinical data that directly compares the metabolic effects of these two drugs, using sophisticated experimental procedures. The goal of the present study was to compare metabolic effects for each drug versus control animals.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Adult female rats were acutely treated with either risperidone (0.1, 0.5, 1, 2, 6 mg\/kg), paliperidone (0.1, 0.5, 1, 2, 6 mg\/kg) or vehicle and subjected to the glucose tolerance test; plasma was collected to measure insulin levels to measure insulin resistance with HOMA-IR. Separate groups of rats were treated with either risperidone (1, 6 mg\/kg), paliperidone (1, 6 mg\/kg) or vehicle, and subjected to the hyperinsulinemic euglycemic clamp.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Fasting glucose levels were increased by all but the lowest dose of risperidone, but only with the highest dose of paliperidone. HOMA-IR increased for both drugs with all but the lowest dose, while the three highest doses decreased glucose tolerance for both drugs. Risperidone and paliperidone both exhibited dose-dependent decreases in the glucose infusion rate in the clamp, reflecting pronounced insulin resistance.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In preclinical models, both risperidone and paliperidone exhibited notable metabolic side-effects that were dose-dependent. Differences between the two were modest, and most notable as effects on fasting glucose.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0246211","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:35:42Z","timestamp":1611862542000},"page":"e0246211","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models"],"prefix":"10.1371","volume":"16","author":[{"given":"Heidi N.","family":"Boyda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica W. Y.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-5108","authenticated-orcid":true,"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-1574","authenticated-orcid":true,"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"issue":"7","key":"pone.0246211.ref001","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis","volume":"157","author":"L Hartling","year":"2012","journal-title":"Ann Intern Med"},{"issue":"10","key":"pone.0246211.ref002","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: A study in 16 countries, 2005\u20132014.","volume":"27","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"pone.0246211.ref003","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11920-013-0355-6","article-title":"Antipsychotic and psychostimulant drug combination therapy in attention deficit\/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.","volume":"15","author":"D Linton","year":"2013","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"pone.0246211.ref004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.15586\/jptcp.v27i3.681","article-title":"Treatment algorithm for the use of psychopharmacological agents in individuals prenatally exposed to alcohol and\/or with diagnosis of fetal alcohol spectrum disorder (FASD).","volume":"27","author":"M Mela","year":"2020","journal-title":"Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique"},{"key":"pone.0246211.ref005","first-page":"23","article-title":"Psychotic and Bipolar Disorders: Antipsychotic Drugs.","volume":"455","author":"SD Holder","year":"2017","journal-title":"FP essentials."},{"issue":"16","key":"pone.0246211.ref006","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"CU Correll","year":"2009","journal-title":"Jama"},{"issue":"1\u20133","key":"pone.0246211.ref007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2010.10.014","article-title":"The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela","volume":"126","author":"T Baptista","year":"2011","journal-title":"Schizophr Res"},{"issue":"2","key":"pone.0246211.ref008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.9758\/cpn.2012.10.2.71","article-title":"Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain\u2014A Critical Review.","volume":"10","author":"GP Reynolds","year":"2012","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"2","key":"pone.0246211.ref009","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.0208e04","article-title":"Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.","volume":"69","author":"DC Henderson","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"pone.0246211.ref010","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2174\/1570159X17666190228113348","article-title":"Association between Serum Lipids and Antipsychotic Response in Schizophrenia.","volume":"17","author":"DD Kim","year":"2019","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"pone.0246211.ref011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-015-1807-1","article-title":"Treatment of clozapine-associated weight gain: a systematic review","volume":"71","author":"Z Whitney","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0246211.ref012","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JCP.0000000000000648","article-title":"Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia.","volume":"37","author":"DD Kim","year":"2017","journal-title":"J Clin Psychopharmacol."},{"issue":"11","key":"pone.0246211.ref013","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111336","article-title":"Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain.","volume":"8","author":"D Grajales","year":"2019","journal-title":"Cells"},{"issue":"3","key":"pone.0246211.ref014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"L Tse","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"pone.0246211.ref015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.","volume":"8","author":"M De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"23","key":"pone.0246211.ref016","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.2174\/1381612821666150619092903","article-title":"Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends.","volume":"21","author":"L Carton","year":"2015","journal-title":"Curr Pharm Des."},{"issue":"11","key":"pone.0246211.ref017","first-page":"1269","article-title":"Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.","volume":"167","author":"E Wooltorton","year":"2002","journal-title":"Cmaj"},{"key":"pone.0246211.ref018","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3389\/fphar.2020.00596","article-title":"The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use.","volume":"11","author":"I Yunusa","year":"2020","journal-title":"Frontiers in pharmacology."},{"issue":"4","key":"pone.0246211.ref019","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/cap.2017.0120","article-title":"Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.","volume":"28","author":"L Xia","year":"2018","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"pone.0246211.ref020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1471-244X-13-248","article-title":"A retrospective study of antipsychotic drug switching in a pediatric population.","volume":"13","author":"D Linton","year":"2013","journal-title":"BMC Psychiatry."},{"issue":"9","key":"pone.0246211.ref021","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","article-title":"Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.","volume":"26","author":"M De Hert","year":"2012","journal-title":"CNS Drugs"},{"key":"pone.0246211.ref022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.","volume":"13","author":"M Solmi","year":"2017","journal-title":"Therapeutics and clinical risk management."},{"key":"pone.0246211.ref023","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis","author":"C Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"issue":"5","key":"pone.0246211.ref024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2146\/ajhp070261","article-title":"Paliperidone for schizophrenia.","volume":"65","author":"C Dolder","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"pone.0246211.ref025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative Pharmacology of Risperidone and Paliperidone.","volume":"15","author":"M. Corena-McLeod","year":"2015","journal-title":"Drugs in R&D"},{"issue":"1\u20133","key":"pone.0246211.ref026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"M Hahn","year":"2011","journal-title":"Schizophr Res"},{"issue":"1","key":"pone.0246211.ref027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms","volume":"125","author":"GP Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"1","key":"pone.0246211.ref028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"HA Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"1","key":"pone.0246211.ref029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone.","volume":"51","author":"J de Leon","year":"2010","journal-title":"Psychosomatics"},{"issue":"438","key":"pone.0246211.ref030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2008.01309.x","article-title":"Schizophrenia and physical health problems.","author":"Y von Hausswolff-Juhlin","year":"2009","journal-title":"Acta Psychiatr Scand Suppl."},{"issue":"4","key":"pone.0246211.ref031","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12170-013-0321-1","article-title":"Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness.","volume":"7","author":"DJ Lang","year":"2013","journal-title":"Curr Cardiovasc Risk Rep."},{"issue":"10","key":"pone.0246211.ref032","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"HN Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"pone.0246211.ref033","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.","volume":"221","author":"KJ Davey","year":"2012","journal-title":"Psychopharmacology (Berl)."},{"issue":"3","key":"pone.0246211.ref034","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.","volume":"7","author":"K Weston-Green","year":"2012","journal-title":"PLoS One."},{"issue":"12","key":"pone.0246211.ref035","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"GC Smith","year":"2008","journal-title":"Diabetologia"},{"issue":"6","key":"pone.0246211.ref036","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"HN Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"pone.0246211.ref037","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"KL Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"pone.0246211.ref038","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model","volume":"108","author":"AF Chintoh","year":"2009","journal-title":"Schizophr Res"},{"issue":"2","key":"pone.0246211.ref039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"S Skrede","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"pone.0246211.ref040","article-title":"Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat","author":"G Jassim","year":"2011","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"pone.0246211.ref041","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"J Ferno","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"issue":"2","key":"pone.0246211.ref042","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"K Weston-Green","year":"2011","journal-title":"Behav Brain Res"},{"issue":"3","key":"pone.0246211.ref043","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/jpet.118.248393","article-title":"AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis","volume":"365","author":"ND Bush","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"pone.0246211.ref044","doi-asserted-by":"crossref","first-page":"14010","DOI":"10.1096\/fj.201901820R","article-title":"AMPK \u03b21 activation suppresses antipsychotic-induced hyperglycemia in mice","volume":"33","author":"H Shamshoum","year":"2019","journal-title":"Faseb j"},{"issue":"8","key":"pone.0246211.ref045","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.","volume":"6","author":"VL Albaugh","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"pone.0246211.ref046","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2008-1815","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men","volume":"95","author":"S Vidarsdottir","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"pone.0246211.ref047","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"J Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"pone.0246211.ref048","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pnpbp.2018.01.004","article-title":"Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies","volume":"83","author":"KJ Burghardt","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"pone.0246211.ref049","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-244X-11-21","article-title":"Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.","volume":"11","author":"I Turkoz","year":"2011","journal-title":"BMC Psychiatry."},{"issue":"6","key":"pone.0246211.ref050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0018578718809269","article-title":"Cost Comparison of Atypical Antipsychotics: Paliperidone ER and Risperidone.","volume":"54","author":"K Luther","year":"2019","journal-title":"Hospital pharmacy."},{"issue":"3","key":"pone.0246211.ref051","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1503\/jpn.150206","article-title":"Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration.","volume":"41","author":"RM Procyshyn","year":"2016","journal-title":"J Psychiatry Neurosci"},{"issue":"2\u20133","key":"pone.0246211.ref052","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2010.07.016","article-title":"Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study","volume":"123","author":"RM Procyshyn","year":"2010","journal-title":"Schizophr Res"},{"issue":"5","key":"pone.0246211.ref053","first-page":"292","article-title":"Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.","volume":"4","author":"HJ Riordan","year":"2011","journal-title":"American health & drug benefits."},{"issue":"2\u20133","key":"pone.0246211.ref054","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain\u2014far from the clinic?","volume":"116","author":"K Weston-Green","year":"2010","journal-title":"Schizophr Res"},{"key":"pone.0246211.ref055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuroscience.2013.10.010","article-title":"Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats","volume":"255","author":"AM Barr","year":"2013","journal-title":"Neuroscience"},{"issue":"3","key":"pone.0246211.ref056","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"HN Boyda","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"pone.0246211.ref057","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1037\/a0031228","article-title":"Antipsychotic polypharmacy increases metabolic dysregulation in female rats.","volume":"21","author":"HN Boyda","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"pone.0246211.ref058","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat","volume":"114","author":"LE van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology (Berl)."},{"issue":"4","key":"pone.0246211.ref059","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1258\/002367798780599866","article-title":"Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink.","volume":"32","author":"A Hem","year":"1998","journal-title":"Lab Anim."},{"issue":"10","key":"pone.0246211.ref060","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/j.1460-9568.2008.06233.x","article-title":"Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins","volume":"27","author":"AM Barr","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"2","key":"pone.0246211.ref061","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1152\/ajpendo.90889.2008","article-title":"Surrogate measures of insulin resistance: of rats, mice, and men","volume":"296","author":"K. Mather","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"pone.0246211.ref062","doi-asserted-by":"crossref","first-page":"e107116","DOI":"10.1371\/journal.pone.0107116","article-title":"An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.","volume":"9","author":"C Wu","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"pone.0246211.ref063","doi-asserted-by":"crossref","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.","volume":"8","author":"HN Boyda","year":"2013","journal-title":"PLoS One."},{"key":"pone.0246211.ref064","first-page":"107717","article-title":"A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models","author":"JWY Yuen","year":"2019","journal-title":"Neuropharmacology"},{"issue":"6","key":"pone.0246211.ref065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.","volume":"37","author":"HN Boyda","year":"2012","journal-title":"J Psychiatry Neurosci"},{"issue":"11","key":"pone.0246211.ref066","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1210\/jc.2010-2167","article-title":"Limitations in surrogate measures of insulin resistance","volume":"95","author":"TA Buchanan","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"pone.0246211.ref067","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1301\/nr.2003.dec.397-412","article-title":"Evaluation of insulin sensitivity in clinical practice and in research settings.","volume":"61","author":"LU Monzillo","year":"2003","journal-title":"Nutr Rev."},{"key":"pone.0246211.ref068","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.10.006","article-title":"Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine","volume":"48","author":"HN Boyda","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"pone.0246211.ref069","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145713000795","article-title":"Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats.","volume":"17","author":"HN Boyda","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"pone.0246211.ref070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2010.07.008","article-title":"The oral glucose tolerance test (OGTT) revisited.","volume":"22","author":"E Bartoli","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"48","key":"pone.0246211.ref071","doi-asserted-by":"crossref","DOI":"10.3791\/2432","article-title":"Hyperinsulinemic-euglycemic clamp in the conscious rat.","author":"CC Hughey","year":"2011","journal-title":"J Vis Exp."},{"issue":"1","key":"pone.0246211.ref072","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"T Baptista","year":"2002","journal-title":"Brain Res"},{"key":"pone.0246211.ref073","doi-asserted-by":"crossref","first-page":"173064","DOI":"10.1016\/j.pbb.2020.173064","article-title":"Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats","author":"E Sylvester","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"pone.0246211.ref074","article-title":"Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018\u2014A pharmacoepidemiology study.","author":"JN Claassen","year":"2020","journal-title":"Research in social & administrative pharmacy: RSAP"},{"issue":"12","key":"pone.0246211.ref075","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1139\/cjpp-2013-0185","article-title":"Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats","volume":"91","author":"S Aboul-Fotouh","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"issue":"8","key":"pone.0246211.ref076","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2337\/dc06-0438","article-title":"Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans","volume":"29","author":"C Meyer","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"pone.0246211.ref077","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/meta.2001.18569","article-title":"Effects of insulin on regional blood flow and glucose uptake in Wistar and Sprague-Dawley rats","volume":"50","author":"N Gaudreault","year":"2001","journal-title":"Metabolism"},{"issue":"6","key":"pone.0246211.ref078","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2002-36391","article-title":"Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.","volume":"35","author":"T Baptista","year":"2002","journal-title":"Pharmacopsychiatry."},{"issue":"1","key":"pone.0246211.ref079","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.1999.tb10908.x","article-title":"Body weight gain induced by antipsychotic drugs: mechanisms and management.","volume":"100","author":"T. Baptista","year":"1999","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"pone.0246211.ref080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"E Richelson","year":"2000","journal-title":"Life Sci"},{"issue":"3","key":"pone.0246211.ref081","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10799893.2015.1091475","article-title":"\u03b11A-Adrenergic receptor prevents cardiac ischemic damage through PKC\u03b4\/GLUT1\/4-mediated glucose uptake","volume":"36","author":"T Shi","year":"2016","journal-title":"Journal of receptor and signal transduction research"},{"issue":"6","key":"pone.0246211.ref082","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/oby.2002.75","article-title":"In vivo response to alpha(1)-adrenoreceptor stimulation in human white adipose tissue.","volume":"10","author":"M Boschmann","year":"2002","journal-title":"Obes Res"},{"issue":"3","key":"pone.0246211.ref083","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/jne.12002","article-title":"Peripheral adrenoceptors: the impetus behind glucose dysregulation and insulin resistance","volume":"25","author":"HN Boyda","year":"2013","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"pone.0246211.ref084","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation.","volume":"36","author":"YE Savoy","year":"2010","journal-title":"Schizophr Bull"},{"issue":"2","key":"pone.0246211.ref085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jphs.2018.11.015","article-title":"5-HT(2A) deletion protects against Clozapine-induced hyperglycemia.","volume":"139","author":"RS Joshi","year":"2019","journal-title":"J Pharmacol Sci"},{"key":"pone.0246211.ref086","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.peptides.2015.07.008","article-title":"Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes.","volume":"71","author":"H Bennet","year":"2015","journal-title":"Peptides"},{"issue":"4","key":"pone.0246211.ref087","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.npp.1301181","article-title":"Risperidone and paliperidone inhibit p-glycoprotein activity in vitro","volume":"32","author":"HJ Zhu","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"pone.0246211.ref088","doi-asserted-by":"crossref","first-page":"104400","DOI":"10.1016\/j.psyneuen.2019.104400","article-title":"Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.","volume":"109","author":"C Kowalchuk","year":"2019","journal-title":"Psychoneuroendocrinology."},{"issue":"6","key":"pone.0246211.ref089","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1503\/jpn.170092","article-title":"In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.","volume":"42","author":"C Kowalchuk","year":"2017","journal-title":"J Psychiatry Neurosci."},{"key":"pone.0246211.ref090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13034-018-0243-2","article-title":"A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents.","volume":"12","author":"T Dodsworth","year":"2018","journal-title":"Child and adolescent psychiatry and mental health."},{"issue":"4","key":"pone.0246211.ref091","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans","volume":"36","author":"M Vermeir","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"pone.0246211.ref092","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00213-001-0933-x","article-title":"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.","volume":"159","author":"M Aravagiri","year":"2002","journal-title":"Psychopharmacology (Berl)."},{"issue":"6","key":"pone.0246211.ref093","first-page":"1134","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"G Mannens","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"pone.0246211.ref094","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2006.04.004","article-title":"Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats","volume":"51","author":"AM Barr","year":"2006","journal-title":"Neuropharmacology"},{"issue":"9896","key":"pone.0246211.ref095","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"S Leucht","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"pone.0246211.ref096","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review.","volume":"14","author":"R Musil","year":"2015","journal-title":"Expert Opin Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:36:10Z","timestamp":1611862570000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246211"}},"subtitle":[],"editor":[{"given":"Kyle J.","family":"Burghardt","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246211","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}